Impact of Arrhythmias on Hospitalizations in Patients With Cardiac Amyloidosis.


Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
15 03 2021
Historique:
received: 28 10 2020
revised: 05 12 2020
accepted: 08 12 2020
pubmed: 23 12 2020
medline: 7 4 2021
entrez: 22 12 2020
Statut: ppublish

Résumé

Cardiac involvement in amyloidosis is associated with a poor prognosis. Data on the burden of arrhythmias in patients with cardiac amyloidosis (CA) during hospitalization are lacking. We identified the burden of arrhythmias using the National Inpatient Sample (NIS) database from January 2016 to December 2017. We compared patient characteristics, outcomes, and hospitalization costs between CA patients with and without documented arrhythmias. Out of 5,585 hospital admissions for CA, 2,020 (36.1%) had concurrent arrhythmias. Propensity-score matching for age, sex, income, and co-morbidities was performed with 1,405 CA patients with arrhythmias and 1,405 patients without. The primary outcome of all-cause mortality was significantly higher in CA patients with arrhythmia than without(13.9% vs 5.3%, p-value <0.001). Atrial fibrillation (AF) was the most common (72.2%) arrhythmia in CA patients with concurrent arrhythmia. The secondary outcomes of AF-related mortality (11.95% vs 9.16%, p-value = 0.02) and acute and acute on chronic as heart failure (HF) exacerbation (32.38% vs 24.91%, p-value <0.0001) were significantly higher in CA and concurrent arrhythmia compared with CA patients without. The total length of hospital stay (6[3 to 12] vs 5[3 to 10], p-value <0.001) and cost of hospitalization were ($ 15,086[7,813 to 30,373] vs $ 12,219[6,865 to 23,997], p-value = 0.001) were significantly greater among CA with arrhythmia compared with those without. These data suggest that the presence of arrhythmias in CA patients during hospital admission is associated with a poorer prognosis and may reflect patients with a higher risk of HF exacerbation and mortality.

Identifiants

pubmed: 33352208
pii: S0002-9149(20)31352-7
doi: 10.1016/j.amjcard.2020.12.024
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

125-130

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Disclosures The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Samarthkumar Thakkar (S)

Department of Internal Medicine, Rochester General Hospital, Rochester, New York.

Harsh P Patel (HP)

Department of Internal Medicine, Louis A Weiss Memorial Hospital, Chicago, Illinois.

Medhat Chowdhury (M)

Department of Internal Medicine, Rochester General Hospital, Rochester, New York.

Kirtenkumar Patel (K)

Department of Cardiology, North Shore University Hospital, Manhasset, New York.

Ashish Kumar (A)

Department of Critical Care Medicine, St John's Medical College Hospital, Bengaluru, Karnataka, India.

Shilpkumar Arora (S)

Department of Cardiology, Case Western University, Cleveland, Ohio.

Salman Zahid (S)

Department of Internal Medicine, Rochester General Hospital, Rochester, New York.

Mishita Goel (M)

Department of Internal Medicine, Wayne State University/APRH, Rochester, Michigan.

Kirolos Barssoum (K)

Department of Internal Medicine, Rochester General Hospital, Rochester, New York.

Vardhmaan Jain (V)

Department of Internal Medicine, Cleveland Clinic, Ohio.

Omar F AbouEzzeddine (OF)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.

Christopher V DeSimone (CV)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.

Bipul Baibhav (B)

Sands Constellation Heart Institute, Rochester Regional Health, Rochester, New York.

Mohan Rao (M)

Sands Constellation Heart Institute, Rochester Regional Health, Rochester, New York.

Abhishek Deshmukh (A)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota. Electronic address: Deshmukh.Abhishek@mayo.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH